Modernizing Medicare Part D

During this congressional lunch briefing, analysts will outline the mechanisms of the Medicare Part D program under current law and discuss the potential implications of reforms put forward by Congress and the administration.

Basics of Biosimilars

During this briefing, panelists explained the mechanisms of biologic drugs, explore the impact of current regulations on the uptake of biosimilars, and discuss considerations for the biosimilars market in the United States.

Our 2018 Speakers

Prescription Drug Costs: Can Increased Competition Restrain Prices?

This webinar will focus on the first approach and will explore different perspectives on how increasing the number of generic and biosimilar options may affect the drug pricing market. Specifically, panelists discussed the main opportunities and challenges of the generic and biosimilar market, how past administrations have approached this issue, and how different stakeholders, including consumers, are impacted.

State Opportunities to Address Prescription Drug Costs in Medicaid

The purpose of this briefing is to orient federal policymakers and stakeholders to the legislative and regulatory actions that state officials are perusing to address the rising cost of prescription drugs in Medicaid. Panelists will outline the rationale for these actions, detail the mechanisms of state policies, and describe opportunities to leverage flexibility within federal parameters.

Chronic Pain & Opioid Addiction: The Role of Integrated Care

The opioid addiction crisis has thrown a spotlight on the physical and behavioral health issues surrounding chronic pain. This briefing examined innovative non-pharmacologic models to address chronic pain, including among the military and veteran population and through state Medicaid and safety net programs.

Medicare and Prescription Drug Prices

This briefing featured presentations by our experts highlighting the trends in Medicare regarding prescription drug pricing, and panelists discussed an array of policy options to align drug prices with value through alternative payment models.

Biosimilars in the United States: Next Steps

With biosimilar biological products moving from the lab to the marketplace, key policy and regulatory questions are being actively debated, with important implications for industry, patients, and the health care system.

Value-Based Pricing for Prescription Drugs: Opportunities and Challenges

Recent pharmaceutical innovations offer unprecedented possibilities for curing, treating, or preventing a range of diseases. However, patients, providers and payers alike have raised concerns about the affordability and sustainability of these drugs. As a response to price increases of both single-source and generic drugs, some stakeholders are calling for a move towards basing payments on value, and some payers and pharmaceutical manufacturers are exploring ways to base payments on outcomes. However, many challenges remain.

Health Care Consolidation: What You Need to Know

A top Federal Trade Commission official, along with key experts, met with reporters Dec. 15 to discuss the recent surge in health care consolidation; the driving forces behind this trend; and the implications for policymakers and enforcers.

Health Care Consolidation: Trends, Impact and Regulation

In 2014, there were a total of 1,299 mergers and acquisitions in the health care sector – a record number, up from 1,035 the year before. This briefing will discussed the driving forces behind this recent increase in consolidation; the scope and extent of consolidation among doctors, hospitals and insurers; implications for consumers and other stakeholders; and the roles of the Department of Justice and the Federal Trade Commission.

Taking the Right Meds at the Right Time: Medication Adherence, Health Outcomes and Costs

Evidence shows that medication adherence—the extent to which a person takes medications as prescribed by their health care providers—is associated with improved health care outcomes for many costly chronic conditions, including heart disease, diabetes, and asthma. However, only 50% percent of Americans are estimated to take their medications as prescribed, and non-adherence is estimated to result in added direct and indirect costs to the healthcare system of over $300 billion per year. The challenges and policy questions surrounding medication adherence affect Medicare, Medicaid, and the private sector – and offer a window into broader questions surrounding the ability of our health care system to coordinate care, particularly for people with multiple chronic conditions. In this briefing, top experts from the public and private sectors explored key policy, practical, and research questions surrounding medication adherence and management of medications.